. . . . "\u85E5\u7269\u8A2D\u8A08\uFF08\u82F1\u8A9E\uFF1ADrug design\uFF09\uFF0C\u53C8\u7A31\u7406\u6027\u85E5\u7269\u8A2D\u8A08\uFF08rational drug design\uFF09\uFF0C\u6839\u64DA\u5C0D\u65BC\u9776\u70B9\uFF08Biological target\uFF09\u7684\u73FE\u6709\u77E5\u8B58\uFF0C\u53BB\u5C0B\u627E\u8207\u767C\u660E\u51FA\u65B0\u578B\u85E5\u7269\u7684\u904E\u7A0B\u3002\u85E5\u7269\u8A2D\u8A08\u6839\u64DA\u6709\u6A5F\u5C0F\u5206\u5B50\u7269\u8CEA\uFF08\u5982\u86CB\u767D\u8CEA\uFF09\u7684\u5316\u5B78\u7D50\u69CB\u3001\u96FB\u50F9\u8207\u5F62\u72C0\u7B49\uFF0C\u4F86\u8A2D\u8A08\u51FA\u53EF\u80FD\u9054\u5230\u6548\u679C\u7684\u65B0\u578B\u5316\u5B78\u85E5\u7269\u3002\u4F7F\u7528\u96FB\u8166\u5206\u5B50\u5EFA\u69CB\u6280\u8853\uFF0C\u4F86\u9032\u884C\u85E5\u7269\u8A2D\u8A08\uFF0C\u7A31\u70BA\u96FB\u8166\u8F14\u52A9\u85E5\u7269\u8A2D\u8A08\uFF08computer-aided drug design\uFF09\u3002\u6839\u64DA\u5C0D\u65BC\u751F\u7269\u76EE\u6A19\u7684\u5316\u5B78\u7D50\u69CB\u4F86\u9032\u884C\u8A2D\u8A08\uFF0C\u7A31\u70BA\u7D50\u69CB\u85E5\u7269\u8A2D\u8A08\uFF08structure-based drug design\uFF09\u3002\u9664\u4E86\u5C0F\u5206\u5B50\u4E4B\u5916\uFF0C\u751F\u7269\u6CBB\u7642\uFF0C\u7279\u5225\u662F\u55AE\u514B\u9686\u6297\u9AD4\u6CBB\u7642\u662F\u8D8A\u4F86\u8D8A\u91CD\u8981\u7684\u4E00\u985E\u85E5\u7269\uFF0C\u4E26\u4E14\u5DF2\u7D93\u958B\u767C\u4E86\u7528\u65BC\u6539\u5584\u9019\u4E9B\u57FA\u65BC\u86CB\u767D\u8CEA\u7684\u6CBB\u7642\u5291\u7684\u89AA\u548C\u529B\uFF0C\u9078\u64C7\u6027\u548C\u7A69\u5B9A\u6027\u7684\u8A08\u7B97\u65B9\u6CD5\u3002"@zh . . . . "\u062A\u0635\u0645\u064A\u0645 \u062F\u0648\u0627\u0621"@ar . . . . . . . . . . . . . . "\u533B\u85AC\u54C1\u8A2D\u8A08"@ja . . "right"@en . . . . . . . . . . "La conception de m\u00E9dicament, plus pr\u00E9cis\u00E9ment conception de substance pharmacologiquement active plus connue sous sa d\u00E9nomination anglaise Drug design est l'ensemble des processus n\u00E9cessaires \u00E0 l'\u00E9laboration d'un m\u00E9dicament. Dans l'industrie pharmaceutique, ces processus peuvent-\u00EAtre subdivis\u00E9s et r\u00E9partis en quatre phases ou \u00E9tapes : 1. \n* La phase de recherche 2. \n* La phase de d\u00E9veloppement 3. \n* La phase clinique 4. \n* La phase de mise sur le march\u00E9 Remarque : Les phases de recherche et d\u00E9veloppement sont commun\u00E9ment d\u00E9nomm\u00E9es R&D."@fr . "Wirkstoffdesign"@de . . . . . . "Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals including peptides and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed. The phrase \"drug design\" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles."@en . . "\u85E5\u7269\u8A2D\u8A08\uFF08\u82F1\u8A9E\uFF1ADrug design\uFF09\uFF0C\u53C8\u7A31\u7406\u6027\u85E5\u7269\u8A2D\u8A08\uFF08rational drug design\uFF09\uFF0C\u6839\u64DA\u5C0D\u65BC\u9776\u70B9\uFF08Biological target\uFF09\u7684\u73FE\u6709\u77E5\u8B58\uFF0C\u53BB\u5C0B\u627E\u8207\u767C\u660E\u51FA\u65B0\u578B\u85E5\u7269\u7684\u904E\u7A0B\u3002\u85E5\u7269\u8A2D\u8A08\u6839\u64DA\u6709\u6A5F\u5C0F\u5206\u5B50\u7269\u8CEA\uFF08\u5982\u86CB\u767D\u8CEA\uFF09\u7684\u5316\u5B78\u7D50\u69CB\u3001\u96FB\u50F9\u8207\u5F62\u72C0\u7B49\uFF0C\u4F86\u8A2D\u8A08\u51FA\u53EF\u80FD\u9054\u5230\u6548\u679C\u7684\u65B0\u578B\u5316\u5B78\u85E5\u7269\u3002\u4F7F\u7528\u96FB\u8166\u5206\u5B50\u5EFA\u69CB\u6280\u8853\uFF0C\u4F86\u9032\u884C\u85E5\u7269\u8A2D\u8A08\uFF0C\u7A31\u70BA\u96FB\u8166\u8F14\u52A9\u85E5\u7269\u8A2D\u8A08\uFF08computer-aided drug design\uFF09\u3002\u6839\u64DA\u5C0D\u65BC\u751F\u7269\u76EE\u6A19\u7684\u5316\u5B78\u7D50\u69CB\u4F86\u9032\u884C\u8A2D\u8A08\uFF0C\u7A31\u70BA\u7D50\u69CB\u85E5\u7269\u8A2D\u8A08\uFF08structure-based drug design\uFF09\u3002\u9664\u4E86\u5C0F\u5206\u5B50\u4E4B\u5916\uFF0C\u751F\u7269\u6CBB\u7642\uFF0C\u7279\u5225\u662F\u55AE\u514B\u9686\u6297\u9AD4\u6CBB\u7642\u662F\u8D8A\u4F86\u8D8A\u91CD\u8981\u7684\u4E00\u985E\u85E5\u7269\uFF0C\u4E26\u4E14\u5DF2\u7D93\u958B\u767C\u4E86\u7528\u65BC\u6539\u5584\u9019\u4E9B\u57FA\u65BC\u86CB\u767D\u8CEA\u7684\u6CBB\u7642\u5291\u7684\u89AA\u548C\u529B\uFF0C\u9078\u64C7\u6027\u548C\u7A69\u5B9A\u6027\u7684\u8A08\u7B97\u65B9\u6CD5\u3002"@zh . . . . "\u041A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432"@uk . . . . "O processo de desenvolvimento de f\u00E1rmacos \u00E9 um processo vagaroso e complicado que necessita de uma grande demanda de tempo e dinheiro. De acordo com Pharmaceutical Research and Manufacturers of America (PhRMA) em 2011 foram gastos 96 bilh\u00F5es de d\u00F3lares pelas 20 principais empresas farmac\u00EAuticas do mundo, considerando que apenas 20% das drogas aprovadas possuem lucros maiores que os gastos para produ\u00E7\u00E3o esse \u00E9 um investimento de grande risco. Desse modo, m\u00E9todos in silico t\u00EAm sido buscados como uma maneira de permitir que esse processo seja acelerado e mais acess\u00EDvel economicamente. Al\u00E9m disso, essas ferramentas permitem, de maneira racional, uma melhor escolha do composto l\u00EDder e uma previs\u00E3o para suas posteriores otimiza\u00E7\u00F5es.Algumas abordagens utilizadas no desenvolvimento de f\u00E1rmacos s\u00E3o"@pt . . . . . . . . . . . . . . . . . . . . . . . . "\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: drug design)\u200F \u060C \u0643\u0645\u0627 \u064A\u0634\u0627\u0631 \u0625\u0644\u064A\u0647 \u0623\u062D\u064A\u0627\u0646\u0627 \u0628\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0639\u0642\u0644\u0627\u0646\u064A (\u0623\u0648 \u0627\u0644\u0645\u0646\u0637\u0642\u064A) \u0623\u0648 \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u0647\u064A\u0643\u0644\u064A\u0629\u060C \u0647\u0648 \u0639\u0645\u0644\u064A\u0629 \u0645\u0628\u062A\u0643\u0631\u0629 \u0644\u0625\u064A\u062C\u0627\u062F \u0623\u062F\u0648\u064A\u0629 \u062C\u062F\u064A\u062F\u0629 \u0645\u0628\u0646\u064A\u0629 \u0639\u0644\u0649 \u0645\u0639\u0631\u0641\u0629 \u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u0628\u064A\u0648\u0644\u0648\u062C\u064A. \u0647\u0630\u0627 \u0627\u0644\u062F\u0648\u0627\u0621 \u0627\u0644\u0630\u064A \u064A\u062A\u0645 \u062A\u0635\u0645\u064A\u0645\u0647 \u0647\u0648 \u0639\u0627\u062F\u0629 \u0645\u0627 \u064A\u0643\u0648\u0646 \u062C\u0632\u064A\u0621 \u0639\u0636\u0648\u064A \u0635\u063A\u064A\u0631 \u064A\u0642\u0648\u0645 \u0628\u062A\u0646\u0634\u064A\u0637 \u0623\u0648 \u062A\u062B\u0628\u064A\u0637 \u0648\u0638\u064A\u0641\u0629 \u0645\u0646 \u062C\u0632\u064A\u0621 \u062D\u064A\u0648\u064A \u0645\u062B\u0644 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0645\u0645\u0651\u0627 \u064A\u0624\u062F\u064A \u0628\u062F\u0648\u0631\u0647 \u0625\u0644\u0649 \u0641\u0648\u0627\u0626\u062F \u0639\u0644\u0627\u062C\u064A\u0629 \u0644\u0644\u0645\u0631\u064A\u0636.\u0628\u0645\u0639\u0646\u0649 \u0628\u0633\u064A\u0637\u060C \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0627\u062F\u0648\u064A\u0629 \u064A\u0646\u0637\u0648\u064A \u0639\u0644\u0649 \u062A\u0635\u0645\u064A\u0645 \u062C\u0632\u064A\u0626\u0627\u062A \u0635\u063A\u064A\u0631\u0629 \u062A\u062A\u0643\u0627\u0645\u0644 \u0641\u064A \u0627\u0644\u0634\u0643\u0644 \u0648\u0641\u064A \u0627\u0644\u0634\u062D\u0646\u0629 \u0627\u0644\u0643\u0647\u0631\u0628\u0627\u0626\u064A\u0629 \u0645\u0639 \u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u062C\u0632\u064A\u0626\u064A \u0627\u0644\u0628\u064A\u0648\u0644\u0648\u062C\u064A \u0648\u062A\u062A\u0641\u0627\u0639\u0644 \u0645\u0639\u0647.\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u064A\u0639\u062A\u0645\u062F \u0628\u0634\u0643\u0644 \u0634\u0627\u0626\u0639 \u0639\u0644\u0649 \u062A\u0642\u0646\u064A\u0627\u062A \u0627\u0644\u0646\u0645\u0630\u062C\u0629 \u0627\u0644\u062D\u0627\u0633\u0648\u0628\u064A\u0629 \u0648\u0644\u0643\u0646 \u0644\u0627 \u064A\u0639\u062A\u0645\u062F \u0628\u0627\u0644\u0636\u0631\u0648\u0631\u0629 \u0639\u0644\u0649 \u0627\u0644\u062D\u0627\u0633\u0648\u0628."@ar . . . . . "Dise\u00F1o de f\u00E1rmaco"@es . . . . . "Drug discovery cycle schematic"@en . . . . . . . . "N\u00E1vrh l\u00E9\u010Div (anglicky Drug design) p\u0159esn\u011Bji ozna\u010Den\u00FD jako racion\u00E1ln\u00ED n\u00E1vrh l\u00E9\u010Div je proces hled\u00E1n\u00ED nov\u00FDch l\u00E9\u010Div zalo\u017Een\u00FD na znalosti biologick\u00FDch c\u00EDl\u016F. L\u00E9\u010Divo je nej\u010Dast\u011Bji mal\u00E1 organick\u00E1 molekula kter\u00E1 aktivuje, nebo inhibuje funkce biomolekul jako jsou nap\u0159\u00EDklad proteiny co\u017E vede k terapeutick\u00E9mu prosp\u011Bchu pacienta. V nejb\u011B\u017En\u011Bj\u0161\u00EDm p\u0159\u00EDpad\u011B n\u00E1vrh l\u00E9\u010Div zahrnuje n\u00E1vrh molekul kter\u00E9 jsou komplement\u00E1rn\u00ED sv\u00FDm tvarem a n\u00E1bojem ke biomolekule na kterou c\u00EDl\u00ED a v\u00E1\u017E\u00ED se na ni. N\u00E1vrh l\u00E9\u010Div \u010Dasto, ale ne nezbytn\u011B z\u00E1vis\u00ED na technik\u00E1ch po\u010D\u00EDta\u010Dov\u00E9ho modelov\u00E1n\u00ED Drug design kter\u00FD je z\u00E1visl\u00FD na 3D struktu\u0159e c\u00EDlen\u00E9 biomolekuly se naz\u00FDv\u00E1 n\u00E1vrh l\u00E9\u010Diva na z\u00E1klad\u011B zn\u00E1m\u00E9 struktury vazebn\u00E9ho m\u00EDsta. Krom\u011B mal\u00FDch organick\u00FDch molekul vzr\u016Fst\u00E1 d\u016Fle\u017Eitost v\u00FDvoje biofarmak na b\u00E1zi peptid\u016F a terapeutick\u00FDch protil\u00E1tek a s t\u00EDm \u010Detnost pou\u017E\u00EDv\u00E1n\u00ED v\u00FDpo\u010Detn\u00EDch metod pro zlep\u0161en\u00ED afinity, selektivity a stability. Fr\u00E1ze \u201En\u00E1vrh l\u00E9\u010Div\u201C je do jist\u00E9 m\u00EDry nep\u0159esn\u00FD pojem. P\u0159esn\u011Bj\u0161\u00EDm term\u00EDnem by byl n\u00E1vrh ligandu (tzn. n\u00E1vrh molekuly, kter\u00E1 se bude pevn\u011B v\u00E1zat na sv\u016Fj c\u00EDl). I p\u0159esto, \u017Ee jsou techniky n\u00E1vrhu designu pro p\u0159edpov\u011B\u010F vazebn\u00E9 afinity vcelku \u00FAsp\u011B\u0161n\u00E9, d\u016Fle\u017Eitou roli hraje tak\u00E9 mnoho jin\u00FDch d\u016Fle\u017Eit\u00FDch vlastnosti vlastnosti jako biodostupnost, biologick\u00FD polo\u010Das, vedlej\u0161\u00ED efekty atd. Tyto parametry se p\u0159edn\u011B mus\u00ED optimalizovat p\u0159ed t\u00EDm, ne\u017E se l\u00E9k stane bezpe\u010Dn\u00FDm a \u00FA\u010Dinn\u00FDm. Zm\u00EDn\u011Bn\u00E9 dal\u0161\u00ED vlastnosti je \u010Dasto obt\u00ED\u017En\u00E9 p\u0159edpov\u00EDdat v\u00FDpo\u010Detn\u00EDmi technikami n\u00E1vrhu l\u00E9\u010Div. Kv\u016Fli vysok\u00E9mu procentu vy\u0159azen\u00FDch l\u00E9\u010Div v klinick\u00E9 f\u00E1zi testov\u00E1n\u00ED se za\u010D\u00EDn\u00E1 kl\u00E1st d\u016Fraz na po\u010D\u00E1te\u010Dn\u00ED proces n\u00E1vrhu a selekci l\u00E9\u010Div jejich\u017E fyzik\u00E1ln\u011B-chemick\u00E9 vlastnosti jsou p\u0159edpov\u011Bzeny jako m\u00E9n\u011B problematick\u00E9 pro v\u00FDvoj l\u00E9ku a povedou tak pravd\u011Bpodobn\u011Bji ke schv\u00E1len\u00ED a prodeji. D\u00E1le se v\u00FDpo\u010Detn\u00EDch metod \u010D\u00EDm d\u00E1l v\u00EDce vyu\u017E\u00EDv\u00E1 jako dopln\u011Bk pro In vitro experimenty v prvopo\u010D\u00E1tc\u00EDch objevu l\u00E9\u010Div pro selekci slou\u010Denin s v\u00EDce p\u0159\u00EDzniv\u00FDm ADME (absorpce, distribuce, metabolismus, exkrece)."@cs . . . "\u85E5\u7269\u8A2D\u8A08"@zh . . . . . . . . . . . . . . . . . . . "O processo de desenvolvimento de f\u00E1rmacos \u00E9 um processo vagaroso e complicado que necessita de uma grande demanda de tempo e dinheiro. De acordo com Pharmaceutical Research and Manufacturers of America (PhRMA) em 2011 foram gastos 96 bilh\u00F5es de d\u00F3lares pelas 20 principais empresas farmac\u00EAuticas do mundo, considerando que apenas 20% das drogas aprovadas possuem lucros maiores que os gastos para produ\u00E7\u00E3o esse \u00E9 um investimento de grande risco. Desse modo, m\u00E9todos in silico t\u00EAm sido buscados como uma maneira de permitir que esse processo seja acelerado e mais acess\u00EDvel economicamente. Al\u00E9m disso, essas ferramentas permitem, de maneira racional, uma melhor escolha do composto l\u00EDder e uma previs\u00E3o para suas posteriores otimiza\u00E7\u00F5es.Algumas abordagens utilizadas no desenvolvimento de f\u00E1rmacos s\u00E3o rela\u00E7\u00F5es estrutura-atividade (SAR) e a rela\u00E7\u00E3o estrutura-atividade quantitativa (QSAR). A adi\u00E7\u00E3o orientada de grupos metila, cloro, hidroxila ou benzo\u00EDla no composto-molde pode melhorar propriedades farmacol\u00F3gicas da mol\u00E9cula. A QSAR \u00E9 uma rela\u00E7\u00E3o matem\u00E1tica que permite a correla\u00E7\u00E3o entre a atividade biol\u00F3gica de um sistema molecular com suas caracter\u00EDsticas geom\u00E9tricas e qu\u00EDmicas, como o coeficiente de parti\u00E7\u00E3o, P. Al\u00E9m disso, o desenho de f\u00E1rmacos com base na estrutura foi poss\u00EDvel a partir da d\u00E9cada de 80 com a determina\u00E7\u00E3o de estruturas moleculares por t\u00E9cnicas como cristalografia de raios X e Resson\u00E2ncia magn\u00E9tica. Desse modo, \u00E9 poss\u00EDvel o planejamento do composto baseado na estrutura do alvo a ser modulado por um agonista ou bloqueado antagonista. O composto-molde \u00E9 a mol\u00E9cula que apresenta o efeito biol\u00F3gico desejado e apresenta algumas caracter\u00EDsticas determinantes, como alta afinidade ao seu alvo."@pt . . . . . . . . . . . . "El dise\u00F1o de f\u00E1rmacos es la forma de encontrar medicamentos mediante dise\u00F1os basados en sus acciones biol\u00F3gicas. El objetivo {destino} de un f\u00E1rmaco t\u00EDpicamente es una mol\u00E9cula clave; o una v\u00EDa metab\u00F3lica particular, la cual es espec\u00EDfica de una enfermedad o patolog\u00EDa; o apunta a la contagiosidad o a la supervivencia de un microbio pat\u00F3geno. Algunos m\u00E9todos procuran detener el funcionamiento de una ruta metab\u00F3lica enferma haciendo que una mol\u00E9cula clave deje de funcionar. Los f\u00E1rmacos pueden ser dise\u00F1ados para unirse a la regi\u00F3n activa de una mol\u00E9cula espec\u00EDfica e inhibirla. Pero, adem\u00E1s, estos f\u00E1rmacos tambi\u00E9n tienen que ser dise\u00F1ados de tal manera que no afecten ninguna otra mol\u00E9cula importante que pueda tener una apariencia similar a la mol\u00E9cula clave. Frecuentemente se usan similitudes en la secuencias {moleculares} para identificar tales riesgos. Otras formas de abordarlo pueden ser el potenciar la v\u00EDa normal estimulando mol\u00E9culas espec\u00EDficas en las v\u00EDas metab\u00F3licas normales que pudieran haber sido afectadas con la enfermedad. La estructura de la mol\u00E9cula de un f\u00E1rmaco que puede interactuar espec\u00EDficamente con las biomol\u00E9culas se puede modelar usando herramientas computacionales. Estas herramientas pueden permitir que una mol\u00E9cula de droga sea construida dentro de la biomol\u00E9cula usando lo que se conoce de su estructura y de la naturaleza de su sitio activo. La construcci\u00F3n de una mol\u00E9cula de f\u00E1rmaco se puede hacer desde dentro hacia fuera o desde afuera hacia dentro, dependiendo de si eligen primero el n\u00FAcleo o a los grupos R. Sin embargo, muchos de estos enfoques est\u00E1n plagados de los problemas pr\u00E1cticos de la s\u00EDntesis qu\u00EDmica. Enfoques m\u00E1s recientes tambi\u00E9n han sugerido el uso de mol\u00E9culas de f\u00E1rmaco grandes y de naturaleza proteica en lugar de mol\u00E9culas peque\u00F1as. Asimismo, ha habido sugerencias para fabricarlos usando ARNm (\u00C1cido Ribonucl\u00E9ico mitocondrial) {en ingl\u00E9s: mRNA}. El silenciamiento de genes puede tambi\u00E9n tener usos terap\u00E9uticos."@es . "Desenho de f\u00E1rmacos"@pt . . "Wirkstoffdesign (auch Rationales Wirkstoffdesign) bezeichnet den gezielten Entwurf von Wirkstoffen. Diese Wirkstoffe dienen unter anderem der Entwicklung von Arzneimitteln oder Pflanzenschutzmitteln. Der gezielte Entwurf von Wirkstoffen basiert auf dem Auffinden und Optimieren von Leitstrukturen, die als Teil eines Liganden an ein Target binden. Wirkstoffdesign ist eine Form des rationalen Designs."@de . . . . . . . . . . . "Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensio"@en . "\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: drug design)\u200F \u060C \u0643\u0645\u0627 \u064A\u0634\u0627\u0631 \u0625\u0644\u064A\u0647 \u0623\u062D\u064A\u0627\u0646\u0627 \u0628\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0639\u0642\u0644\u0627\u0646\u064A (\u0623\u0648 \u0627\u0644\u0645\u0646\u0637\u0642\u064A) \u0623\u0648 \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0627\u0644\u0647\u064A\u0643\u0644\u064A\u0629\u060C \u0647\u0648 \u0639\u0645\u0644\u064A\u0629 \u0645\u0628\u062A\u0643\u0631\u0629 \u0644\u0625\u064A\u062C\u0627\u062F \u0623\u062F\u0648\u064A\u0629 \u062C\u062F\u064A\u062F\u0629 \u0645\u0628\u0646\u064A\u0629 \u0639\u0644\u0649 \u0645\u0639\u0631\u0641\u0629 \u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u0628\u064A\u0648\u0644\u0648\u062C\u064A. \u0647\u0630\u0627 \u0627\u0644\u062F\u0648\u0627\u0621 \u0627\u0644\u0630\u064A \u064A\u062A\u0645 \u062A\u0635\u0645\u064A\u0645\u0647 \u0647\u0648 \u0639\u0627\u062F\u0629 \u0645\u0627 \u064A\u0643\u0648\u0646 \u062C\u0632\u064A\u0621 \u0639\u0636\u0648\u064A \u0635\u063A\u064A\u0631 \u064A\u0642\u0648\u0645 \u0628\u062A\u0646\u0634\u064A\u0637 \u0623\u0648 \u062A\u062B\u0628\u064A\u0637 \u0648\u0638\u064A\u0641\u0629 \u0645\u0646 \u062C\u0632\u064A\u0621 \u062D\u064A\u0648\u064A \u0645\u062B\u0644 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0645\u0645\u0651\u0627 \u064A\u0624\u062F\u064A \u0628\u062F\u0648\u0631\u0647 \u0625\u0644\u0649 \u0641\u0648\u0627\u0626\u062F \u0639\u0644\u0627\u062C\u064A\u0629 \u0644\u0644\u0645\u0631\u064A\u0636.\u0628\u0645\u0639\u0646\u0649 \u0628\u0633\u064A\u0637\u060C \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0627\u062F\u0648\u064A\u0629 \u064A\u0646\u0637\u0648\u064A \u0639\u0644\u0649 \u062A\u0635\u0645\u064A\u0645 \u062C\u0632\u064A\u0626\u0627\u062A \u0635\u063A\u064A\u0631\u0629 \u062A\u062A\u0643\u0627\u0645\u0644 \u0641\u064A \u0627\u0644\u0634\u0643\u0644 \u0648\u0641\u064A \u0627\u0644\u0634\u062D\u0646\u0629 \u0627\u0644\u0643\u0647\u0631\u0628\u0627\u0626\u064A\u0629 \u0645\u0639 \u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u062C\u0632\u064A\u0626\u064A \u0627\u0644\u0628\u064A\u0648\u0644\u0648\u062C\u064A \u0648\u062A\u062A\u0641\u0627\u0639\u0644 \u0645\u0639\u0647.\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u064A\u0639\u062A\u0645\u062F \u0628\u0634\u0643\u0644 \u0634\u0627\u0626\u0639 \u0639\u0644\u0649 \u062A\u0642\u0646\u064A\u0627\u062A \u0627\u0644\u0646\u0645\u0630\u062C\u0629 \u0627\u0644\u062D\u0627\u0633\u0648\u0628\u064A\u0629 \u0648\u0644\u0643\u0646 \u0644\u0627 \u064A\u0639\u062A\u0645\u062F \u0628\u0627\u0644\u0636\u0631\u0648\u0631\u0629 \u0639\u0644\u0649 \u0627\u0644\u062D\u0627\u0633\u0648\u0628. \u0648\u0627\u0644\u062F\u0648\u0627\u0621 \u0647\u0648 \u062C\u0632\u064A\u0621 \u0639\u0636\u0648\u064A \u0635\u063A\u064A\u0631 \u0644\u0647 \u062F\u0648\u0631 \u0641\u064A \u062A\u0646\u0634\u064A\u0637 \u062C\u0632\u064A\u0621 \u062D\u064A\u0648\u064A \u0622\u062E\u0631 \u0623\u0648 \u0645\u0646\u0639 \u0648\u0638\u064A\u0641\u062A\u0647 \u0645\u062B\u0644 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u060C \u0645\u0645\u0627 \u064A\u0624\u062F\u064A \u0625\u0644\u0649 \u0641\u0627\u0626\u062F\u0629 \u0639\u0644\u0627\u062C\u064A\u0629 \u0644\u0644\u0645\u0631\u064A\u0636. \u0648\u064A\u0645\u0643\u0646 \u0623\u0646 \u0646\u0628\u0633\u0637 \u0627\u0644\u0645\u0639\u0646\u0649 \u0627\u0644\u0633\u0627\u0628\u0642 \u0644\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 \u0628\u0642\u0648\u0644\u0646\u0627 \u0625\u0646\u0647 \u064A\u062A\u0636\u0645\u0646 \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062C\u0632\u064A\u0626\u0627\u062A \u0627\u0644\u062A\u064A \u062A\u0631\u062A\u0628\u0637 \u0628\u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u062D\u064A\u0648\u064A \u0627\u0644\u062C\u0632\u064A\u0626\u064A \u0648\u062A\u062A\u0641\u0627\u0639\u0644 \u0645\u0639\u0647\u060C \u0648\u0647\u064A \u0645\u0643\u0645\u0644\u0629 \u0644\u0647 \u0641\u064A \u0627\u0644\u0634\u0643\u0644 \u0648\u0627\u0644\u0634\u062D\u0646\u0629. \u0648\u063A\u0627\u0644\u0628\u0627\u064B \u0645\u0627 \u064A\u0633\u062A\u062E\u062F\u0645 \u0627\u0644\u062D\u0627\u0633\u0648\u0628 \u0641\u064A \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 _ \u0648\u064A\u0633\u0645\u0649 \u0647\u0630\u0627 \u0627\u0644\u0646\u0648\u0639 \u0645\u0646 \u0627\u0644\u062A\u0635\u0645\u064A\u0645 \u0628\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 \u0628\u0645\u0633\u0627\u0639\u062F\u0629 \u0627\u0644\u062D\u0627\u0633\u0648\u0628 \u0648\u0644\u0643\u0646 \u0644\u064A\u0633 \u0645\u0646 \u0627\u0644\u0636\u0631\u0648\u0631\u064A \u0623\u0646 \u064A\u0639\u062A\u0645\u062F \u0639\u0644\u064A\u0647 \u0628\u0634\u0643\u0644 \u0643\u0644\u064A. \u0648\u064A\u0639\u062A\u0645\u062F \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621 \u0639\u0644\u0649 \u0645\u0639\u0631\u0641\u0629 \u0627\u0644\u0647\u064A\u0643\u0644 \u062B\u0644\u0627\u062B\u064A \u0627\u0644\u0623\u0628\u0639\u0627\u062F \u0644\u0644\u0647\u062F\u0641 \u0627\u0644\u062C\u0632\u064A\u0626\u064A \u0627\u0644\u062D\u064A\u0648\u064A \u0648\u0627\u0644\u0645\u0639\u0631\u0648\u0641 \u0628\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0642\u0627\u0626\u0645\u0629 \u0639\u0644\u0649 \u0627\u0644\u0647\u064A\u0643\u0644 \u0627\u0644\u062D\u064A\u0648\u064A\u060C \u0648\u0623\u064A\u0636\u0627\u064B \u064A\u0639\u062A\u0645\u062F \u0639\u0644\u0649 \u0627\u0644\u062C\u0632\u064A\u0626\u0627\u062A \u0627\u0644\u0635\u063A\u064A\u0631\u0629 \u0648 (\u0627\u0644\u0645\u0633\u062A\u062D\u0636\u0631\u0627\u062A \u0627\u0644\u0635\u064A\u062F\u0644\u0627\u0646\u064A\u0629 (\u062E\u0627\u0635\u0629 \u0627\u0644\u0623\u062C\u0633\u0627\u0645 \u0627\u0644\u0639\u0644\u0627\u062C\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629. \u0644\u0647\u0630\u0627 \u0641\u0627\u0644\u0628\u0639\u0636 \u064A\u0631\u0649 \u0623\u0646 \u0639\u0628\u0627\u0631\u0629 (\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621) \u062A\u0639\u062F - \u0625\u0644\u0649 \u062D\u062F \u0645\u0627 - \u062A\u0633\u0645\u064A\u0629 \u063A\u064A\u0631 \u062F\u0642\u064A\u0642\u0629 \u0648\u0627\u0644\u062A\u0633\u0645\u064A\u0629 \u0627\u0644\u0623\u0643\u062B\u0631 \u062F\u0642\u0629 \u0647\u064A (\u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062C\u0632\u064A\u0621) \u0627\u0644\u0630\u064A \u0633\u064A\u0631\u062A\u0628\u0637 \u0628\u0625\u062D\u0643\u0627\u0645 \u0645\u0639 \u0627\u0644\u0647\u062F\u0641 \u0627\u0644\u0645\u062D\u062F\u062F. \u0648\u0639\u0644\u0649 \u0627\u0644\u0631\u063A\u0645 \u0645\u0646 \u0623\u0646\u064E \u062A\u0642\u0646\u064A\u0629 \u0627\u0644\u062A\u0635\u0645\u064A\u0645 \u062A\u0643\u0648\u0646 \u0646\u0627\u062C\u062D\u0629\u060C \u0625\u0644\u0627\u064E \u0623\u0646 \u0647\u0646\u0627\u0643 \u0627\u0644\u0639\u062F\u064A\u062F \u0645\u0646 \u0627\u0644\u062E\u0635\u0627\u0626\u0635 \u0627\u0644\u0623\u062E\u0631\u0649 \u0627\u0644\u062A\u064A \u064A\u062C\u0628 \u0623\u0646 \u064A\u0643\u0648\u0646 \u0644\u0647\u0627 \u0627\u0644\u0623\u0647\u0645\u064A\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0644\u0643\u064A \u064A\u0639\u062F \u0627\u0644\u062F\u0648\u0627\u0621 \u0622\u0645\u0646\u0627 \u0648\u0641\u0639\u064E\u0627\u0644\u0627 \u0642\u0628\u0644 \u062A\u0635\u0645\u064A\u0645\u0647\u060C (\u0645\u062B\u0644 \u0627\u0644\u062A\u0648\u0627\u0641\u0631 \u0627\u0644\u062D\u064A\u0648\u064A\u060C \u0639\u0645\u0631 \u0627\u0644\u0646\u0635\u0641\u060C \u0639\u0645\u0644\u064A\u0627\u062A \u0627\u0644\u0623\u064A\u0636 , \u0627\u0644\u0622\u062B\u0627\u0631 \u0627\u0644\u062C\u0627\u0646\u0628\u064A\u0629 \u0648\u063A\u064A\u0631\u0647\u0627..), \u0648\u0645\u0639 \u0630\u0644\u0643 \u0647\u0646\u0627\u0643 \u062E\u0635\u0627\u0626\u0635 \u0623\u062E\u0631\u0649 \u064A\u0635\u0639\u0628 \u0627\u0644\u062A\u0646\u0628\u0624 \u0628\u0647\u0627 \u0628\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0647\u0630\u0647 \u0627\u0644\u062A\u0642\u0646\u064A\u0629. \u0648\u0646\u0638\u0631\u0627\u064B \u0644\u0627\u0631\u062A\u0641\u0627\u0639 \u0645\u0639\u062F\u0644\u0627\u062A \u0627\u0644\u0627\u0633\u062A\u0646\u0632\u0627\u0641 -attrition rates\u2013 \u0623\u062B\u0646\u0627\u0621 \u062A\u0635\u0645\u064A\u0645 \u0627\u0644\u062F\u0648\u0627\u0621\u060C \u0641\u0625\u0646\u0647 \u064A\u062C\u0628 \u0623\u0646 \u064A\u0643\u0648\u0646 \u0627\u0644\u0627\u0646\u062A\u0628\u0627\u0647 \u0645\u0631\u0643\u0632\u0627\u064B \u0639\u0644\u0649 \u0627\u0644\u062E\u0635\u0627\u0626\u0635 \u0627\u0644\u0641\u064A\u0632\u064A\u0627\u0626\u064A\u0629 \u0648\u0627\u0644\u0643\u064A\u0645\u064A\u0627\u0626\u064A\u0629 \u0627\u0644\u0645\u062A\u0648\u0642\u0639 \u0623\u0646 \u062A\u0624\u062F\u064A \u0625\u0644\u0649 \u0645\u0636\u0627\u0639\u0641\u0627\u062A \u0623\u0642\u0644\u060C \u0648\u0628\u0647\u0630\u0627 \u062A\u062A\u0645 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u064A\u0647 \u0648\u0625\u062F\u0631\u0627\u062C\u0647 \u0641\u064A \u0627\u0644\u0623\u0633\u0648\u0627\u0642."@ar . . . . . . . . "\u533B\u85AC\u54C1\u8A2D\u8A08\uFF08\u3044\u3084\u304F\u3072\u3093\u305B\u3063\u3051\u3044\u3001\u82F1: Drug design; \u30C9\u30E9\u30C3\u30B0\u30C7\u30B6\u30A4\u30F3\uFF09\u3068\u306F\u3001\u751F\u7269\u5B66\u7684\u6A19\u7684\u306E\u77E5\u8B58\u306B\u57FA\u3065\u3044\u3066\u65B0\u3057\u3044\u85AC\u7269\u3092\u898B\u51FA\u3059\u5275\u610F\u306B\u5BCC\u3093\u3060\u624B\u6CD5\u3067\u3042\u308B\u3002\u3057\u3070\u3057\u3070\u5408\u7406\u7684\u533B\u85AC\u54C1\u8A2D\u8A08\u307E\u305F\u306F\u5358\u306B\u5408\u7406\u7684\u8A2D\u8A08\u3068\u3082\u547C\u3070\u308C\u308B\u3002\u85AC\u7269\u306F\u3001\u30BF\u30F3\u30D1\u30AF\u8CEA\u306A\u3069\u306E\u751F\u4F53\u5206\u5B50\u306E\u6A5F\u80FD\u3092\u6D3B\u6027\u5316\u307E\u305F\u306F\u963B\u5BB3\u3059\u308B\u6709\u6A5F\u4F4E\u5206\u5B50\u304C\u6700\u3082\u4E00\u822C\u7684\u3067\u3042\u308A\u3001\u3053\u308C\u306B\u3088\u308A\u60A3\u8005\u306B\u3092\u3082\u305F\u3089\u3059\u3002\u6700\u3082\u57FA\u672C\u7684\u306A\u610F\u5473\u3067\u306E\u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u76F8\u4E92\u4F5C\u7528\u3059\u308B\u751F\u4F53\u5206\u5B50\u6A19\u7684\u3068\u76F8\u88DC\u7684\u306A\u5F62\u72B6\u3068\u96FB\u8377\u3092\u6301\u3061\u3001\u6A19\u7684\u306B\u7D50\u5408\u3059\u308B\u5206\u5B50\u3092\u8A2D\u8A08\u3059\u308B\u3053\u3068\u3092\u542B\u3080\u3002\u305D\u306E\u4ED6\u306B\u3082\u3001\u901A\u5E38\u306E\u7D4C\u8DEF\u3092\u5F37\u5316\u3059\u308B\u305F\u3081\u306B\u3001\u75C5\u6C17\u306E\u5834\u5408\u306B\u5F71\u97FF\u3092\u53D7\u3051\u3066\u3044\u308B\u3067\u3042\u308D\u3046\u7279\u5B9A\u306E\u5206\u5B50\u306E\u50CD\u304D\u3092\u4FC3\u9032\u3059\u308B\u65B9\u6CD5\u3082\u3042\u308B\u3002 \u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u30B3\u30F3\u30D4\u30E5\u30FC\u30BF\u6280\u8853\u3092\u7528\u3044\u3066\u30E2\u30C7\u30EB\u5316\u3059\u308B\u3053\u3068\u304C\u3067\u304D\u3001\u30B3\u30F3\u30D4\u30E5\u30FC\u30BF\u652F\u63F4\u5275\u85AC\u8A2D\u8A08\u3068\u3082\u547C\u3070\u308C\u308B\u3002\u307E\u305F\u3001\u751F\u4F53\u5206\u5B50\u6A19\u7684\u306E\u4E09\u6B21\u5143\u69CB\u9020\u306E\u77E5\u8B58\u306B\u4F9D\u5B58\u3057\u305F\u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u69CB\u9020\u30D9\u30FC\u30B9\u85AC\u7269\u8A2D\u8A08\u3068\u3057\u3066\u77E5\u3089\u308C\u3066\u3044\u308B\u3002\u3053\u308C\u3089\u306E\u6280\u8853\u306F\u3001\u6D3B\u6027\u90E8\u4F4D\u306E\u69CB\u9020\u3068\u6027\u8CEA\u306E\u77E5\u898B\u304B\u3089\u751F\u4F53\u5206\u5B50\u306B\u3046\u307E\u304F\u7D44\u307F\u5408\u3046\u5206\u5B50\u306E\u69CB\u7BC9\u3092\u53EF\u80FD\u306B\u3059\u308B\u3002 \u4F4E\u5206\u5B50\u306B\u52A0\u3048\u3066\u3001\u30DA\u30D7\u30C1\u30C9\u3001\u7279\u306B\u6CBB\u7642\u7528\u6297\u4F53\u3092\u542B\u3080\u30D0\u30A4\u30AA\u533B\u85AC\u54C1\u306F\u307E\u3059\u307E\u3059\u91CD\u8981\u3067\u3001\u3053\u308C\u3089\u306E\u30BF\u30F3\u30D1\u30AF\u8CEA\u30D9\u30FC\u30B9\u306E\u6CBB\u7642\u85AC\u306E\u89AA\u548C\u6027\u3001\u9078\u629E\u6027\u3001\u304A\u3088\u3073\u5B89\u5B9A\u6027\u3092\u5411\u4E0A\u3055\u305B\u308B\u305F\u3081\u306E\u8A08\u7B97\u7684\u624B\u6CD5\u3082\u958B\u767A\u3055\u308C\u3066\u3044\u308B\u3002"@ja . . . . . . . "Wirkstoffdesign (auch Rationales Wirkstoffdesign) bezeichnet den gezielten Entwurf von Wirkstoffen. Diese Wirkstoffe dienen unter anderem der Entwicklung von Arzneimitteln oder Pflanzenschutzmitteln. Der gezielte Entwurf von Wirkstoffen basiert auf dem Auffinden und Optimieren von Leitstrukturen, die als Teil eines Liganden an ein Target binden. Wirkstoffdesign ist eine Form des rationalen Designs."@de . . . . . . . "\u041A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432, \u0449\u043E \u0447\u0430\u0441\u0442\u043E \u0437\u0433\u0430\u0434\u0443\u0454\u0442\u044C\u0441\u044F \u044F\u043A \u0440\u0430\u0446\u0456\u043E\u043D\u0430\u043B\u044C\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0430\u0431\u043E \u043F\u0440\u043E\u0441\u0442\u043E \u0440\u0430\u0446\u0456\u043E\u043D\u0430\u043B\u044C\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F, - \u0432\u0438\u043D\u0430\u0445\u0456\u0434\u043D\u0438\u0446\u044C\u043A\u0438\u0439 \u043F\u0440\u043E\u0446\u0435\u0441 \u043F\u043E\u0448\u0443\u043A\u0443/\u0441\u0442\u0432\u043E\u0440\u0435\u043D\u043D\u044F \u043D\u043E\u0432\u0438\u0445 \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u0445 \u0437\u0430\u0441\u043E\u0431\u0456\u0432, \u0431\u0430\u0437\u043E\u0432\u0430\u043D\u0438\u0439, \u044F\u043A \u043F\u0440\u0430\u0432\u0438\u043B\u043E, \u043D\u0430 \u0437\u043D\u0430\u043D\u043D\u044F\u0445 \u043F\u0440\u043E \u0431\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u0443 \u043C\u0456\u0448\u0435\u043D\u044C. \u041D\u0430\u0439\u0447\u0430\u0441\u0442\u0456\u0448\u0435 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0454 \u043C\u0430\u043B\u043E\u044E \u043E\u0440\u0433\u0430\u043D\u0456\u0447\u043D\u043E\u044E \u043C\u043E\u043B\u0435\u043A\u0443\u043B\u043E\u044E, \u0449\u043E \u0430\u043A\u0442\u0438\u0432\u0443\u0454 (\u0456\u043D\u0434\u0443\u043A\u0443\u0454) \u0447\u0438 \u043F\u0440\u0438\u0433\u043D\u0456\u0447\u0443\u0454 (\u0456\u043D\u0433\u0456\u0431\u0443\u0454) \u0444\u0443\u043D\u043A\u0446\u0456\u044E \u0431\u0456\u043E\u043C\u043E\u043B\u0435\u043A\u0443\u043B\u0438, \u044F\u043A \u043F\u0440\u0430\u0432\u0438\u043B\u043E \u0431\u0456\u043B\u043A\u043E\u0432\u043E\u0457 \u043F\u0440\u0438\u0440\u043E\u0434\u0438, \u0449\u043E, \u0443 \u0441\u0432\u043E\u044E \u0447\u0435\u0440\u0433\u0443, \u0432\u0438\u0440\u0430\u0436\u0430\u0454\u0442\u044C\u0441\u044F \u0432 \u0442\u0435\u0440\u0430\u043F\u0435\u0432\u0442\u0438\u0447\u043D\u0456\u0439 \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u0456. \u0423 \u0448\u0438\u0440\u043E\u043A\u043E\u043C\u0443 \u0440\u043E\u0437\u0443\u043C\u0456\u043D\u043D\u0456, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0432\u043A\u043B\u044E\u0447\u0430\u0454 \u0440\u043E\u0437\u0440\u043E\u0431\u043A\u0443 \u043C\u043E\u043B\u0435\u043A\u0443\u043B, \u0449\u043E \u0454 \u043A\u043E\u043C\u043F\u043B\u0435\u043C\u0435\u043D\u0442\u0430\u0440\u043D\u0438\u043C\u0438 \u0437\u0430 \u0444\u043E\u0440\u043C\u043E\u044E \u0442\u0430 \u0437\u0430\u0440\u044F\u0434\u043E\u043C \u0434\u043E \u0431\u0456\u043E\u043C\u043E\u043B\u0435\u043A\u0443\u043B\u044F\u0440\u043D\u043E\u0457 \u043C\u0456\u0448\u0435\u043D\u0456, \u0437 \u044F\u043A\u043E\u044E \u0432\u043E\u043D\u0438 \u0432\u0437\u0430\u0454\u043C\u043E\u0434\u0456\u044E\u0442\u044C/\u0437\u0432\u2019\u044F\u0437\u0443\u044E\u0442\u044C\u0441\u044F. \u0427\u0430\u0441\u0442\u043E, \u0430\u043B\u0435 \u043D\u0435 \u043E\u0431\u043E\u0432'\u044F\u0437\u043A\u043E\u0432\u043E, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0441\u043F\u0438\u0440\u0430\u0454\u0442\u044C\u0441\u044F \u043D\u0430 \u043C\u0435\u0442\u043E\u0434\u0438 \u043A\u043E\u043C\u043F'\u044E\u0442\u0435\u0440\u043D\u043E\u0433\u043E \u043C\u043E\u0434\u0435\u043B\u044E\u0432\u0430\u043D\u043D\u044F. \u0426\u0435\u0439 \u0442\u0438\u043F \u043C\u043E\u0434\u0435\u043B\u044E\u0432\u0430\u043D\u043D\u044F \u0456\u043D\u043E\u0434\u0456 \u043D\u0430\u0437\u0438\u0432\u0430\u044E\u0442\u044C \u043A\u043E\u043C\u043F'\u044E\u0442\u0435\u0440\u043D\u0438\u043C \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F\u043C \u043B\u0456\u043A\u0456\u0432 (computer-aided drug design CADD). \u0423 \u0441\u0432\u043E\u044E \u0447\u0435\u0440\u0433\u0443, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432, \u044F\u043A\u0435 \u043E\u043F\u0438\u0440\u0430\u0454\u0442\u044C\u0441\u044F \u043D\u0430 \u0456\u043D\u0444\u043E\u0440\u043C\u0430\u0446\u0456\u044E \u043F\u0440\u043E \u0442\u0440\u0438\u0432\u0438\u043C\u0456\u0440\u043D\u0443 \u0431\u0443\u0434\u043E\u0432\u0443 \u0431\u0456\u043E\u043C\u0456\u0448\u0435\u043D\u0456, \u0432\u0456\u0434\u043E\u043C\u0435 \u044F\u043A \u0441\u0442\u0440\u0443\u043A\u0442\u0443\u0440a-\u043E\u0440\u0456\u0454\u043D\u0442\u043E\u0432\u0430\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 (structure-based drug design) a\u0431\u043E, \u0447\u0430\u0441\u0442\u0456\u0448\u0435, \u043C\u0456\u0448\u0435\u043D\u044C-\u043E\u0440\u0456\u0454\u043D\u0442\u043E\u0432\u0430\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F (target-based drug design). \u041E\u043A\u0440\u0456\u043C \u043C\u0430\u043B\u0438\u0445 \u043C\u043E\u043B\u0435\u043A\u0443\u043B, \u0431\u0456\u043E\u0444\u0430\u0440\u043C\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043D\u0456 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0438 (\u043D\u0430\u043F\u0440\u0438\u043A\u043B\u0430\u0434 \u0442\u0435\u0440\u0430\u043F\u0435\u0432\u0442\u0438\u0447\u043D\u0456 \u0430\u043D\u0442\u0438\u0442\u0456\u043B\u0430) \u0441\u0442\u0430\u044E\u0442\u044C \u0434\u0435\u0434\u0430\u043B\u0456 \u0432\u0430\u0436\u043B\u0438\u0432\u0456\u0448\u0438\u043C \u043A\u043B\u0430\u0441\u043E\u043C \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u0445 \u0437\u0430\u0441\u043E\u0431\u0456\u0432; \u0432 \u0446\u044C\u043E\u043C\u0443 \u0432\u0438\u043F\u0430\u0434\u043A\u0443 \u0442\u0430\u043A\u043E\u0436 \u0440\u043E\u0437\u0440\u043E\u0431\u043B\u0435\u043D\u0456 \u043E\u0431\u0447\u0438\u0441\u043B\u044E\u0432\u0430\u043B\u044C\u043D\u0456 \u043C\u0435\u0442\u043E\u0434\u0438 \u0434\u043B\u044F \u043F\u043E\u043A\u0440\u0430\u0449\u0435\u043D\u043D\u044F \u0457\u0445 \u0441\u043F\u043E\u0440\u0456\u0434\u043D\u0435\u043D\u043E\u0441\u0442\u0456, \u0441\u0435\u043B\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u0456 \u0442\u0430 \u0441\u0442\u0430\u0431\u0456\u043B\u044C\u043D\u043E\u0441\u0442\u0456. \u0424\u0440\u0430\u0437\u0430 \"\u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u0445 \u0437\u0430\u0441\u043E\u0431\u0456\u0432\" \u0454 \u043F\u0435\u0432\u043D\u043E\u044E \u043C\u0456\u0440\u043E\u044E \u0445\u0438\u0431\u043D\u043E\u044E. \u0411\u0456\u043B\u044C\u0448 \u0442\u043E\u0447\u043D\u0438\u0439 \u0442\u0435\u0440\u043C\u0456\u043D - \u0446\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u0433\u0430\u043D\u0434\u0456\u0432 (\u043D\u0430\u043F\u0440\u0438\u043A\u043B\u0430\u0434, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043C\u043E\u043B\u0435\u043A\u0443\u043B\u0438, \u044F\u043A\u0430 \u0431\u0443\u0434\u0435 \u0432\u0437\u0430\u0454\u043C\u043E\u0434\u0456\u044F\u0442\u0438/\u0437\u0432'\u044F\u0437\u0443\u0432\u0430\u0442\u0438\u0441\u044F \u0437 \u043C\u0456\u0448\u0435\u043D\u043D\u044E). \u0425\u043E\u0447\u0430 \u0441\u0443\u0447\u0430\u0441\u043D\u0456 \u043F\u0456\u0434\u0445\u043E\u0434\u0438 \u0434\u043E \u043F\u0440\u043E\u0433\u043D\u043E\u0437\u0443\u0432\u0430\u043D\u043D\u044F \u0430\u0444\u0456\u043D\u043D\u043E\u0441\u0442\u0456 \u0454 \u0434\u043E\u0441\u0438\u0442\u044C \u0443\u0441\u043F\u0456\u0448\u043D\u0438\u043C\u0438, \u0456\u0441\u043D\u0443\u0454 \u0431\u0430\u0433\u0430\u0442\u043E \u0456\u043D\u0448\u0438\u0445 \u0432\u043B\u0430\u0441\u0442\u0438\u0432\u043E\u0441\u0442\u0435\u0439 \u043C\u043E\u043B\u0435\u043A\u0443\u043B (\u0442\u0430\u043A\u0438\u0445 \u044F\u043A \u0431\u0456\u043E\u0434\u043E\u0441\u0442\u0443\u043F\u043D\u0456\u0441\u0442\u044C, \u043C\u0435\u0442\u0430\u0431\u043E\u043B\u0456\u0447\u043D\u0438\u0439 \u043F\u0435\u0440\u0456\u043E\u0434 \u043D\u0430\u043F\u0456\u0432\u0440\u043E\u0437\u043F\u0430\u0434\u0443, \u043F\u043E\u0431\u0456\u0447\u043D\u0456 \u0435\u0444\u0435\u043A\u0442\u0438 \u0456 \u0442.\u0434.), \u044F\u043A\u0456 \u043F\u043E\u0432\u0438\u043D\u043D\u0456 \u0431\u0443\u0442\u0438 \u043E\u043F\u0442\u0438\u043C\u0456\u0437\u043E\u0432\u0430\u043D\u0456, \u043F\u0435\u0440\u0448 \u043D\u0456\u0436 \u043B\u0456\u0433\u0430\u043D\u0434 \u0441\u0442\u0430\u043D\u0435 \u0431\u0435\u0437\u043F\u0435\u0447\u043D\u0438\u043C \u0456 \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u0438\u043C \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u043E\u043C. \u0426\u0456 \u0445\u0430\u0440\u0430\u043A\u0442\u0435\u0440\u0438\u0441\u0442\u0438\u043A\u0438 \u0447\u0430\u0441\u0442\u043E \u0432\u0430\u0436\u043A\u043E \u043F\u0435\u0440\u0435\u0434\u0431\u0430\u0447\u0438\u0442\u0438 \u0437\u0430 \u0434\u043E\u043F\u043E\u043C\u043E\u0433\u043E\u044E \u0440\u0430\u0446\u0456\u043E\u043D\u0430\u043B\u044C\u043D\u0438\u0445 \u043C\u0435\u0442\u043E\u0434\u0456\u0432 \u043F\u0440\u043E\u0435\u043A\u0442\u0443\u0432\u0430\u043D\u043D\u044F. \u0422\u0438\u043C \u043D\u0435 \u043C\u0435\u043D\u0448\u0435, \u0447\u0435\u0440\u0435\u0437 \u0432\u0438\u0441\u043E\u043A\u0438\u0439 \u0440\u0456\u0432\u0435\u043D\u044C \u0432\u0456\u0434\u0441\u0456\u044E\u0432\u0430\u043D\u043D\u044F, \u043E\u0441\u043E\u0431\u043B\u0438\u0432\u043E \u043F\u0456\u0434 \u0447\u0430\u0441 \u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0438\u0445 \u0435\u0442\u0430\u043F\u0456\u0432 \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F \u043F\u043E\u0442\u0435\u043D\u0446\u0456\u0439\u043D\u043E\u0433\u043E \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u043E\u0433\u043E \u0437\u0430\u0441\u043E\u0431\u0443, \u0432 \u043F\u0440\u043E\u0446\u0435\u0441\u0456 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0431\u0456\u043B\u044C\u0448\u0435 \u0443\u0432\u0430\u0433\u0438 \u0437\u043E\u0441\u0435\u0440\u0435\u0434\u0436\u0443\u044E\u0442\u044C \u043D\u0430 \u0432\u0438\u0431\u043E\u0440\u0456 \u043A\u0430\u043D\u0434\u0438\u0434\u0430\u0442\u0456\u0432 \u0443 \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u0439 \u0437\u0430\u0441\u0456\u0431 (drug-candidates), \u0444\u0456\u0437\u0438\u043A\u043E-\u0445\u0456\u043C\u0456\u0447\u043D\u0456 \u0432\u043B\u0430\u0441\u0442\u0438\u0432\u043E\u0441\u0442\u0456 \u044F\u043A\u0438\u0445, \u043F\u0440\u043E\u0433\u043D\u043E\u0437\u043E\u0432\u0430\u043D\u043E, \u043F\u0440\u0438\u0437\u0432\u0435\u0434\u0443\u0442\u044C \u0434\u043E \u043C\u0435\u043D\u0448\u0438\u0445 \u0443\u0441\u043A\u043B\u0430\u0434\u043D\u0435\u043D\u044C \u0443 \u043F\u0440\u043E\u0446\u0435\u0441\u0456 \u0440\u043E\u0437\u0440\u043E\u0431\u043A\u0438 \u0442\u0430, \u044F\u043A \u043D\u0430\u0441\u043B\u0456\u0434\u043E\u043A, \u0434\u043E \u0441\u0442\u0432\u043E\u0440\u0435\u043D\u043D\u044F \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u043E\u0433\u043E \u0437\u0430\u0441\u043E\u0431\u0443. \u041A\u0440\u0456\u043C \u0442\u043E\u0433\u043E, in vitro \u0434\u043E\u0441\u043B\u0456\u0434\u0436\u0435\u043D\u043D\u044F, \u0434\u043E\u043F\u043E\u0432\u043D\u0435\u043D\u0456 \u043E\u0431\u0447\u0438\u0441\u043B\u044E\u0432\u0430\u043B\u044C\u043D\u0438\u043C\u0438 \u043C\u0435\u0442\u043E\u0434\u0430\u043C\u0438, \u0432\u0441\u0435 \u0447\u0430\u0441\u0442\u0456\u0448\u0435 \u0432\u0438\u043A\u043E\u0440\u0438\u0441\u0442\u043E\u0432\u0443\u044E\u0442\u044C\u0441\u044F \u043D\u0430 \u0440\u0430\u043D\u043D\u0456\u0445 \u0435\u0442\u0430\u043F\u0430\u0445 \u0441\u0442\u0432\u043E\u0440\u0435\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0434\u043B\u044F \u0432\u0456\u0434\u0431\u043E\u0440\u0443 \u0441\u043F\u043E\u043B\u0443\u043A \u0437 \u0431\u0456\u043B\u044C\u0448 \u0441\u043F\u0440\u0438\u044F\u0442\u043B\u0438\u0432\u0438\u043C\u0438 ADME (\u043F\u043E\u0433\u043B\u0438\u043D\u0430\u043D\u043D\u044F (Absorbtion), \u0440\u043E\u0437\u043F\u043E\u0434\u0456\u043B (Distribution), \u043C\u0435\u0442\u0430\u0431\u043E\u043B\u0456\u0437\u043C (Metabolism) \u0442\u0430 \u0435\u043B\u0456\u043C\u0456\u043D\u0430\u0446\u0456\u044F (Elimination)) \u0456 \u0442\u043E\u043A\u0441\u0438\u043A\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u0438\u043C\u0438 \u043F\u0440\u043E\u0444\u0456\u043B\u044F\u043C\u0438."@uk . . "225"^^ . . . "Conception de m\u00E9dicament"@fr . . . . "300"^^ . . "300"^^ . . . "Drug design"@en . . . . . . . . . . "1100990633"^^ . "El dise\u00F1o de f\u00E1rmacos es la forma de encontrar medicamentos mediante dise\u00F1os basados en sus acciones biol\u00F3gicas. El objetivo {destino} de un f\u00E1rmaco t\u00EDpicamente es una mol\u00E9cula clave; o una v\u00EDa metab\u00F3lica particular, la cual es espec\u00EDfica de una enfermedad o patolog\u00EDa; o apunta a la contagiosidad o a la supervivencia de un microbio pat\u00F3geno. Otras formas de abordarlo pueden ser el potenciar la v\u00EDa normal estimulando mol\u00E9culas espec\u00EDficas en las v\u00EDas metab\u00F3licas normales que pudieran haber sido afectadas con la enfermedad."@es . . . . . . "\u041A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432, \u0449\u043E \u0447\u0430\u0441\u0442\u043E \u0437\u0433\u0430\u0434\u0443\u0454\u0442\u044C\u0441\u044F \u044F\u043A \u0440\u0430\u0446\u0456\u043E\u043D\u0430\u043B\u044C\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0430\u0431\u043E \u043F\u0440\u043E\u0441\u0442\u043E \u0440\u0430\u0446\u0456\u043E\u043D\u0430\u043B\u044C\u043D\u0435 \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F, - \u0432\u0438\u043D\u0430\u0445\u0456\u0434\u043D\u0438\u0446\u044C\u043A\u0438\u0439 \u043F\u0440\u043E\u0446\u0435\u0441 \u043F\u043E\u0448\u0443\u043A\u0443/\u0441\u0442\u0432\u043E\u0440\u0435\u043D\u043D\u044F \u043D\u043E\u0432\u0438\u0445 \u043B\u0456\u043A\u0430\u0440\u0441\u044C\u043A\u0438\u0445 \u0437\u0430\u0441\u043E\u0431\u0456\u0432, \u0431\u0430\u0437\u043E\u0432\u0430\u043D\u0438\u0439, \u044F\u043A \u043F\u0440\u0430\u0432\u0438\u043B\u043E, \u043D\u0430 \u0437\u043D\u0430\u043D\u043D\u044F\u0445 \u043F\u0440\u043E \u0431\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u0443 \u043C\u0456\u0448\u0435\u043D\u044C. \u041D\u0430\u0439\u0447\u0430\u0441\u0442\u0456\u0448\u0435 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0454 \u043C\u0430\u043B\u043E\u044E \u043E\u0440\u0433\u0430\u043D\u0456\u0447\u043D\u043E\u044E \u043C\u043E\u043B\u0435\u043A\u0443\u043B\u043E\u044E, \u0449\u043E \u0430\u043A\u0442\u0438\u0432\u0443\u0454 (\u0456\u043D\u0434\u0443\u043A\u0443\u0454) \u0447\u0438 \u043F\u0440\u0438\u0433\u043D\u0456\u0447\u0443\u0454 (\u0456\u043D\u0433\u0456\u0431\u0443\u0454) \u0444\u0443\u043D\u043A\u0446\u0456\u044E \u0431\u0456\u043E\u043C\u043E\u043B\u0435\u043A\u0443\u043B\u0438, \u044F\u043A \u043F\u0440\u0430\u0432\u0438\u043B\u043E \u0431\u0456\u043B\u043A\u043E\u0432\u043E\u0457 \u043F\u0440\u0438\u0440\u043E\u0434\u0438, \u0449\u043E, \u0443 \u0441\u0432\u043E\u044E \u0447\u0435\u0440\u0433\u0443, \u0432\u0438\u0440\u0430\u0436\u0430\u0454\u0442\u044C\u0441\u044F \u0432 \u0442\u0435\u0440\u0430\u043F\u0435\u0432\u0442\u0438\u0447\u043D\u0456\u0439 \u0435\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u0456. \u0423 \u0448\u0438\u0440\u043E\u043A\u043E\u043C\u0443 \u0440\u043E\u0437\u0443\u043C\u0456\u043D\u043D\u0456, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0432\u043A\u043B\u044E\u0447\u0430\u0454 \u0440\u043E\u0437\u0440\u043E\u0431\u043A\u0443 \u043C\u043E\u043B\u0435\u043A\u0443\u043B, \u0449\u043E \u0454 \u043A\u043E\u043C\u043F\u043B\u0435\u043C\u0435\u043D\u0442\u0430\u0440\u043D\u0438\u043C\u0438 \u0437\u0430 \u0444\u043E\u0440\u043C\u043E\u044E \u0442\u0430 \u0437\u0430\u0440\u044F\u0434\u043E\u043C \u0434\u043E \u0431\u0456\u043E\u043C\u043E\u043B\u0435\u043A\u0443\u043B\u044F\u0440\u043D\u043E\u0457 \u043C\u0456\u0448\u0435\u043D\u0456, \u0437 \u044F\u043A\u043E\u044E \u0432\u043E\u043D\u0438 \u0432\u0437\u0430\u0454\u043C\u043E\u0434\u0456\u044E\u0442\u044C/\u0437\u0432\u2019\u044F\u0437\u0443\u044E\u0442\u044C\u0441\u044F. \u0427\u0430\u0441\u0442\u043E, \u0430\u043B\u0435 \u043D\u0435 \u043E\u0431\u043E\u0432'\u044F\u0437\u043A\u043E\u0432\u043E, \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F \u043B\u0456\u043A\u0456\u0432 \u0441\u043F\u0438\u0440\u0430\u0454\u0442\u044C\u0441\u044F \u043D\u0430 \u043C\u0435\u0442\u043E\u0434\u0438 \u043A\u043E\u043C\u043F'\u044E\u0442\u0435\u0440\u043D\u043E\u0433\u043E \u043C\u043E\u0434\u0435\u043B\u044E\u0432\u0430\u043D\u043D\u044F. \u0426\u0435\u0439 \u0442\u0438\u043F \u043C\u043E\u0434\u0435\u043B\u044E\u0432\u0430\u043D\u043D\u044F \u0456\u043D\u043E\u0434\u0456 \u043D\u0430\u0437\u0438\u0432\u0430\u044E\u0442\u044C \u043A\u043E\u043C\u043F'\u044E\u0442\u0435\u0440\u043D\u0438\u043C \u043A\u043E\u043D\u0441\u0442\u0440\u0443\u044E\u0432\u0430\u043D\u043D\u044F\u043C \u043B\u0456\u043A\u0456\u0432 (computer-aided dr"@uk . . . "\u533B\u85AC\u54C1\u8A2D\u8A08\uFF08\u3044\u3084\u304F\u3072\u3093\u305B\u3063\u3051\u3044\u3001\u82F1: Drug design; \u30C9\u30E9\u30C3\u30B0\u30C7\u30B6\u30A4\u30F3\uFF09\u3068\u306F\u3001\u751F\u7269\u5B66\u7684\u6A19\u7684\u306E\u77E5\u8B58\u306B\u57FA\u3065\u3044\u3066\u65B0\u3057\u3044\u85AC\u7269\u3092\u898B\u51FA\u3059\u5275\u610F\u306B\u5BCC\u3093\u3060\u624B\u6CD5\u3067\u3042\u308B\u3002\u3057\u3070\u3057\u3070\u5408\u7406\u7684\u533B\u85AC\u54C1\u8A2D\u8A08\u307E\u305F\u306F\u5358\u306B\u5408\u7406\u7684\u8A2D\u8A08\u3068\u3082\u547C\u3070\u308C\u308B\u3002\u85AC\u7269\u306F\u3001\u30BF\u30F3\u30D1\u30AF\u8CEA\u306A\u3069\u306E\u751F\u4F53\u5206\u5B50\u306E\u6A5F\u80FD\u3092\u6D3B\u6027\u5316\u307E\u305F\u306F\u963B\u5BB3\u3059\u308B\u6709\u6A5F\u4F4E\u5206\u5B50\u304C\u6700\u3082\u4E00\u822C\u7684\u3067\u3042\u308A\u3001\u3053\u308C\u306B\u3088\u308A\u60A3\u8005\u306B\u3092\u3082\u305F\u3089\u3059\u3002\u6700\u3082\u57FA\u672C\u7684\u306A\u610F\u5473\u3067\u306E\u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u76F8\u4E92\u4F5C\u7528\u3059\u308B\u751F\u4F53\u5206\u5B50\u6A19\u7684\u3068\u76F8\u88DC\u7684\u306A\u5F62\u72B6\u3068\u96FB\u8377\u3092\u6301\u3061\u3001\u6A19\u7684\u306B\u7D50\u5408\u3059\u308B\u5206\u5B50\u3092\u8A2D\u8A08\u3059\u308B\u3053\u3068\u3092\u542B\u3080\u3002\u305D\u306E\u4ED6\u306B\u3082\u3001\u901A\u5E38\u306E\u7D4C\u8DEF\u3092\u5F37\u5316\u3059\u308B\u305F\u3081\u306B\u3001\u75C5\u6C17\u306E\u5834\u5408\u306B\u5F71\u97FF\u3092\u53D7\u3051\u3066\u3044\u308B\u3067\u3042\u308D\u3046\u7279\u5B9A\u306E\u5206\u5B50\u306E\u50CD\u304D\u3092\u4FC3\u9032\u3059\u308B\u65B9\u6CD5\u3082\u3042\u308B\u3002 \u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u30B3\u30F3\u30D4\u30E5\u30FC\u30BF\u6280\u8853\u3092\u7528\u3044\u3066\u30E2\u30C7\u30EB\u5316\u3059\u308B\u3053\u3068\u304C\u3067\u304D\u3001\u30B3\u30F3\u30D4\u30E5\u30FC\u30BF\u652F\u63F4\u5275\u85AC\u8A2D\u8A08\u3068\u3082\u547C\u3070\u308C\u308B\u3002\u307E\u305F\u3001\u751F\u4F53\u5206\u5B50\u6A19\u7684\u306E\u4E09\u6B21\u5143\u69CB\u9020\u306E\u77E5\u8B58\u306B\u4F9D\u5B58\u3057\u305F\u533B\u85AC\u54C1\u8A2D\u8A08\u306F\u3001\u69CB\u9020\u30D9\u30FC\u30B9\u85AC\u7269\u8A2D\u8A08\u3068\u3057\u3066\u77E5\u3089\u308C\u3066\u3044\u308B\u3002\u3053\u308C\u3089\u306E\u6280\u8853\u306F\u3001\u6D3B\u6027\u90E8\u4F4D\u306E\u69CB\u9020\u3068\u6027\u8CEA\u306E\u77E5\u898B\u304B\u3089\u751F\u4F53\u5206\u5B50\u306B\u3046\u307E\u304F\u7D44\u307F\u5408\u3046\u5206\u5B50\u306E\u69CB\u7BC9\u3092\u53EF\u80FD\u306B\u3059\u308B\u3002 \u4F4E\u5206\u5B50\u306B\u52A0\u3048\u3066\u3001\u30DA\u30D7\u30C1\u30C9\u3001\u7279\u306B\u6CBB\u7642\u7528\u6297\u4F53\u3092\u542B\u3080\u30D0\u30A4\u30AA\u533B\u85AC\u54C1\u306F\u307E\u3059\u307E\u3059\u91CD\u8981\u3067\u3001\u3053\u308C\u3089\u306E\u30BF\u30F3\u30D1\u30AF\u8CEA\u30D9\u30FC\u30B9\u306E\u6CBB\u7642\u85AC\u306E\u89AA\u548C\u6027\u3001\u9078\u629E\u6027\u3001\u304A\u3088\u3073\u5B89\u5B9A\u6027\u3092\u5411\u4E0A\u3055\u305B\u308B\u305F\u3081\u306E\u8A08\u7B97\u7684\u624B\u6CD5\u3082\u958B\u767A\u3055\u308C\u3066\u3044\u308B\u3002 \u300C\u533B\u85AC\u54C1\u8A2D\u8A08\u300D\u3068\u3044\u3046\u8A00\u8449\u306F\u5B9F\u969B\u306B\u306F\u3067\u3042\u308A\u3001\u3088\u308A\u6B63\u78BA\u306A\u7528\u8A9E\u306F\u3001\u30EA\u30AC\u30F3\u30C9\u8A2D\u8A08 (\u3059\u306A\u308F\u3061\u3001\u6A19\u7684\u306B\u5F37\u56FA\u306B\u7D50\u5408\u3059\u308B\u5206\u5B50\u306E\u8A2D\u8A08) \u3067\u3042\u308B\u3002\u7D50\u5408\u89AA\u548C\u6027\u3092\u4E88\u6E2C\u3059\u308B\u305F\u3081\u306E\u8A2D\u8A08\u6280\u8853\u306F\u304B\u306A\u308A\u6210\u529F\u3057\u3066\u3044\u308B\u304C\u3001\u30D0\u30A4\u30AA\u30A2\u30D9\u30A4\u30E9\u30D3\u30EA\u30C6\u30A3\u3001\u4EE3\u8B1D\u534A\u6E1B\u671F\u3001\u526F\u4F5C\u7528\u306A\u3069\u3001\u30EA\u30AC\u30F3\u30C9\u304C\u5B89\u5168\u3067\u6709\u52B9\u306A\u85AC\u7269\u306B\u306A\u308B\u524D\u306B\u3001\u307E\u305A\u6700\u9069\u5316\u3057\u306A\u3051\u308C\u3070\u306A\u3089\u306A\u3044\u4ED6\u306E\u591A\u304F\u306E\u7279\u6027\u304C\u3042\u308B\u3002\u3053\u308C\u3089\u306E\u4ED6\u306E\u7279\u6027\u306F\u3001\u5408\u7406\u7684\u8A2D\u8A08\u6280\u8853\u3067\u306F\u4E88\u6E2C\u304C\u96E3\u3057\u3044\u3053\u3068\u304C\u591A\u3044\u3002\u305D\u308C\u306B\u3082\u304B\u304B\u308F\u3089\u305A\u3001\u7279\u306B\u533B\u85AC\u54C1\u958B\u767A\u306E\u81E8\u5E8A\u6BB5\u968E\u3067\u306F\u96E2\u8131\u7387\u304C\u9AD8\u3044\u305F\u3081\u3001\u533B\u85AC\u54C1\u8A2D\u8A08\u306E\u521D\u671F\u6BB5\u968E\u3067\u306F\u3001\u958B\u767A\u4E2D\u306E\u5408\u4F75\u75C7\u304C\u5C11\u306A\u304F\u3001\u3057\u305F\u304C\u3063\u3066\u627F\u8A8D\u3055\u308C\u3001\u4E0A\u5E02\u3055\u308C\u308B\u53EF\u80FD\u6027\u304C\u9AD8\u3044\u3068\u4E88\u6E2C\u3055\u308C\u308B\u7269\u7406\u5316\u5B66\u7684\u7279\u6027\u3092\u6709\u3059\u308B\u5019\u88DC\u85AC\u3092\u9078\u629E\u3059\u308B\u3053\u3068\u306B\u591A\u304F\u306E\u95A2\u5FC3\u304C\u6255\u308F\u308C\u3066\u3044\u308B\u3002\u3055\u3089\u306B\u3001\u3088\u308A\u826F\u597D\u306AADME (\u5438\u53CE\u3001\u5206\u5E03\u3001\u4EE3\u8B1D\u3001\u6392\u6CC4) \u304A\u3088\u3073\u6BD2\u6027\u30D7\u30ED\u30D5\u30A1\u30A4\u30EB\u3092\u6709\u3059\u308B\u5316\u5408\u7269\u3092\u9078\u629E\u3059\u308B\u305F\u3081\u306B\u3001\u8A08\u7B97\u6CD5\u3092\u88DC\u5B8C\u3059\u308Bin vitro\u5B9F\u9A13\u304C\u5275\u85AC\u306E\u521D\u671F\u6BB5\u968E\u3067\u4F7F\u7528\u3055\u308C\u308B\u3088\u3046\u306B\u306A\u3063\u3066\u304D\u3066\u3044\u308B\u3002"@ja . . "579414"^^ . . . . . . . . . . . . . . . . . . "40603"^^ . . . . . . . . . . . "La conception de m\u00E9dicament, plus pr\u00E9cis\u00E9ment conception de substance pharmacologiquement active plus connue sous sa d\u00E9nomination anglaise Drug design est l'ensemble des processus n\u00E9cessaires \u00E0 l'\u00E9laboration d'un m\u00E9dicament. Dans l'industrie pharmaceutique, ces processus peuvent-\u00EAtre subdivis\u00E9s et r\u00E9partis en quatre phases ou \u00E9tapes : 1. \n* La phase de recherche 2. \n* La phase de d\u00E9veloppement 3. \n* La phase clinique 4. \n* La phase de mise sur le march\u00E9 Remarque : Les phases de recherche et d\u00E9veloppement sont commun\u00E9ment d\u00E9nomm\u00E9es R&D. Pour concevoir un m\u00E9dicament, il faut au pr\u00E9alable le chercher, l'identifier. Cette recherche, qui porte le nom de d\u00E9couverte de m\u00E9dicament ou drug discovery en anglais, s'est fond\u00E9e sur diff\u00E9rentes approches ou strat\u00E9gies, au cours de ces derniers mill\u00E9naires."@fr . . . . . . . . "N\u00E1vrh l\u00E9\u010Div"@cs . . . . . . "N\u00E1vrh l\u00E9\u010Div (anglicky Drug design) p\u0159esn\u011Bji ozna\u010Den\u00FD jako racion\u00E1ln\u00ED n\u00E1vrh l\u00E9\u010Div je proces hled\u00E1n\u00ED nov\u00FDch l\u00E9\u010Div zalo\u017Een\u00FD na znalosti biologick\u00FDch c\u00EDl\u016F. L\u00E9\u010Divo je nej\u010Dast\u011Bji mal\u00E1 organick\u00E1 molekula kter\u00E1 aktivuje, nebo inhibuje funkce biomolekul jako jsou nap\u0159\u00EDklad proteiny co\u017E vede k terapeutick\u00E9mu prosp\u011Bchu pacienta. V nejb\u011B\u017En\u011Bj\u0161\u00EDm p\u0159\u00EDpad\u011B n\u00E1vrh l\u00E9\u010Div zahrnuje n\u00E1vrh molekul kter\u00E9 jsou komplement\u00E1rn\u00ED sv\u00FDm tvarem a n\u00E1bojem ke biomolekule na kterou c\u00EDl\u00ED a v\u00E1\u017E\u00ED se na ni. N\u00E1vrh l\u00E9\u010Div \u010Dasto, ale ne nezbytn\u011B z\u00E1vis\u00ED na technik\u00E1ch po\u010D\u00EDta\u010Dov\u00E9ho modelov\u00E1n\u00ED Drug design kter\u00FD je z\u00E1visl\u00FD na 3D struktu\u0159e c\u00EDlen\u00E9 biomolekuly se naz\u00FDv\u00E1 n\u00E1vrh l\u00E9\u010Diva na z\u00E1klad\u011B zn\u00E1m\u00E9 struktury vazebn\u00E9ho m\u00EDsta. Krom\u011B mal\u00FDch organick\u00FDch molekul vzr\u016Fst\u00E1 d\u016Fle\u017Eitost v\u00FDvoje biofarmak na b\u00E1zi peptid\u016F a terapeutick\u00FDch protil\u00E1tek a s"@cs . . . . . . . .